Free Trial

Alkermes (ALKS) Competitors

Alkermes logo
$31.45 +0.47 (+1.52%)
Closing price 04:00 PM Eastern
Extended Trading
$30.72 -0.72 (-2.31%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALKS vs. ABEO, MEDP, OMCL, AMN, UTHR, INCY, NBIX, EXAS, IONS, and BMRN

Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector.

Alkermes vs. Its Competitors

Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Alkermes has a net margin of 23.15% compared to Abeona Therapeutics' net margin of 0.00%. Abeona Therapeutics' return on equity of 89.05% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Abeona TherapeuticsN/A 89.05% 45.64%
Alkermes 23.15%24.86%17.14%

In the previous week, Alkermes had 4 more articles in the media than Abeona Therapeutics. MarketBeat recorded 10 mentions for Alkermes and 6 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 0.74 beat Abeona Therapeutics' score of 0.09 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alkermes
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abeona Therapeutics currently has a consensus target price of $19.50, indicating a potential upside of 256.49%. Alkermes has a consensus target price of $42.00, indicating a potential upside of 33.55%. Given Abeona Therapeutics' higher possible upside, equities research analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Alkermes
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.93

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abeona Therapeutics$3.50M80.14-$63.73M$0.707.81
Alkermes$1.51B3.45$367.07M$2.0815.12

Abeona Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 5.4% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alkermes beats Abeona Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALKS vs. The Competition

MetricAlkermesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.19B$3.43B$6.11B$10.62B
Dividend YieldN/A2.27%5.72%4.85%
P/E Ratio15.1223.2429.2227.30
Price / Sales3.45270.27491.48184.03
Price / Cash11.4145.2825.8230.35
Price / Book3.4810.6612.476.65
Net Income$367.07M-$52.56M$3.32B$276.14M
7 Day Performance-1.53%4.97%1.87%0.01%
1 Month Performance13.17%16.48%8.40%3.60%
1 Year Performance13.50%14.95%63.49%32.76%

Alkermes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
4.6466 of 5 stars
$31.45
+1.5%
$42.00
+33.5%
+9.6%$5.19B$1.51B15.121,800News Coverage
Upcoming Earnings
ABEO
Abeona Therapeutics
4.3392 of 5 stars
$5.50
+2.2%
$19.50
+254.5%
-17.5%$282.04M$3.50M7.8690News Coverage
MEDP
Medpace
4.341 of 5 stars
$544.41
+3.1%
$430.60
-20.9%
+52.8%$15.29B$2.11B40.485,900Positive News
Upcoming Earnings
OMCL
Omnicell
3.4499 of 5 stars
$30.20
+1.0%
$46.71
+54.7%
-26.5%$1.39B$1.11B60.403,670Positive News
AMN
AMN Healthcare Services
4.3434 of 5 stars
$19.77
+0.5%
$23.08
+16.8%
-51.8%$757.40M$2.98B-2.542,968Short Interest ↓
UTHR
United Therapeutics
4.8 of 5 stars
$432.69
-0.1%
$457.21
+5.7%
+17.4%$19.52B$2.88B16.891,305Analyst Forecast
Insider Trade
INCY
Incyte
4.597 of 5 stars
$86.17
-1.6%
$84.79
-1.6%
+29.8%$16.83B$4.24B19.582,617Upcoming Earnings
Analyst Downgrade
NBIX
Neurocrine Biosciences
4.6482 of 5 stars
$141.33
+0.9%
$163.72
+15.8%
+19.8%$14.02B$2.36B41.811,800Trending News
Upcoming Earnings
Analyst Forecast
EXAS
Exact Sciences
4.4598 of 5 stars
$62.73
+2.4%
$69.19
+10.3%
-12.8%$11.88B$2.76B-11.557,000Analyst Revision
IONS
Ionis Pharmaceuticals
3.4277 of 5 stars
$73.55
+0.6%
$78.50
+6.7%
+85.4%$11.72B$705M-39.971,069
BMRN
BioMarin Pharmaceutical
4.9787 of 5 stars
$53.07
-0.4%
$93.26
+75.7%
-24.3%$10.19B$2.85B15.753,040

Related Companies and Tools


This page (NASDAQ:ALKS) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners